
# Get Ready for Percutaneous Mitral Valve Approaches

Paul A. Grayburn, MD
Baylor Scott and White Healthcare System
The Heart Hospital Baylor Plano and Baylor Heart and
Vascular Hospital
Dallas, TX



HOPE – Unmet Need: There are patients with severe MR who need something done and are too high risk for surgery

HYPE – Wall Street Mentality: There are not millions of these patients, and we are not yet sure who benefits and who does not


## Four Transcatheter Approaches

- Edge-to-edge clip (Alfieri-type) repair (MitraClip FDA approved)
- Annuloplasty
- Chordal replacement
- Mitral valve replacement (TMVR)

# Transcatheter Mitral Valve Repair MitraClip® System




#### MitraClip Worldwide Experience



#### MitraClip is Good but there are Issues

- Failure to eliminate MR
  - Is moderate (2+) good enough?
  - Residual severe (3-4+) in 5-10% of patients
- Late recurrence of MR
  - · Reduces option for surgical repair
- Mitral stenosis
  - MPG < 5 mmHg in cath lab can be worse when patient is ambulatory

Transcatheter Annuloplasty



#### Carillon Device



#### Carillon Pivotal FDA IDE Trial

- 400 patient trial in 50 sites in US, Canada, Europe and Australia
- Blinded, sham-controlled
- 2:1 randomization
- Co-Primary Efficacy Endpoints
  - 1st Primary endpoint: Hierarchical Endpoint
    - Death, Heart Failure, 6 minute walk-test at 12 months
  - 2<sup>nd</sup> Co-Primary Efficacy Endpoint
    - Reduction in Regurgitant Volume at 12 months in treatment group compared to control group

# Transcatheter Mitral Annuloplasty in Chronic Functional Mitral Regurgitation



6-Month Results With the Cardioband Percutaneous Mitral Repair System

Georg Nickenig, MD,<sup>a</sup> Christoph Hammerstingl, MD,<sup>a</sup> Robert Schueler, MD,<sup>a</sup> Yan Topilsky, MD,<sup>b</sup> Paul A. Grayburn, MD,<sup>c</sup> Alec Vahanian, MD,<sup>d</sup> David Messika-Zeitoun, MD,<sup>d</sup> Marina Urena Alcazar, MD,<sup>d</sup> Stephan Baldus, MD,<sup>e</sup> Rudolph Volker, MD,<sup>e</sup> Michael Huntgeburth, MD,<sup>e</sup> Ottavio Alfieri, MD,<sup>f</sup> Azeem Latib, MD,<sup>f</sup> Giovanni La Canna, MD,<sup>f</sup> Eustachio Agricola, MD,<sup>f</sup> Antonio Colombo, MD,<sup>g,h</sup> Karl-Heinz Kuck, MD,<sup>i</sup> Felix Kreidel, MD,<sup>i</sup> Christian Frerker, MD,<sup>i</sup> Felix C. Tanner, MD,<sup>j</sup> Ori Ben-Yehuda, MD,<sup>k</sup> Francesco Maisano, MD<sup>j</sup>

J Am Coll Cardiol Intv 2016;9:2037-49.


#### Cardioband is a Transfemoral Adjustable Ring


Surgery



Cardioband








Secondary (functional) MR is a Disease of the LV; not the mitral annulus!

**Chord Replacement** 




#### NeoChord Pivotal Trial

- 440 randomized pts, plus roll-in patients
- 20 sites
- Co-PIs David Adams/Michael Borger
- Primary effectiveness endpoint freedom from mod/sev MR at 1 year and freedom from mitral valve replacement or reintervention
- Primary safety endpoint freedom from death, stroke, MAE (MVARC def) at 30 days

#### Severe MR




# NeoChord Device - Grasp



# Neochords Attached



# Final Result





#### Chord Replacement: Caveats


- Still a thoracotomy; needs to become transfemoral, transseptal
- Benefit of off-pump not clear in CABG trials
- MVR often done minimally invasively now
- Early European results show late recurrence of MR (learning curve?)


#### Transcatheter Mitral Valve Replacement (TMVR)

- In light of CTSN trials, TMVR offers potentially lower risk option for valve replacement
- Technically more challenging than TAVR
  - Mitral annulus geometry
  - Larger orifice area
- Multiple devices under development
  - Transapical easier; EFS nearly done, pivotal startup
  - Transfemoral already starting










# Different Designs for the Same Thing




Over time, TMVR devices will get smaller and better!

# Finger at LV Apex






















JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
© 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION
PUBLISHED BY ELSEVIER


VOL. ■, NO. ■, 2016
ISSN 0735-1097/\$36.00
http://dx.doi.org/10.1016/j.jacc.2016.10.068


#### Transcatheter Mitral Valve Replacement for Patients With Symptomatic Mitral Regurgitation

A Global Feasibility Trial

David W.M. Muller, MBBS, MD,<sup>a</sup> Robert Saeid Farivar, MD,<sup>b</sup> Paul Jansz, MBBS, PHD,<sup>a</sup> Richard Bae, MD,<sup>b</sup> Darren Walters, MBBS, MPhIL,<sup>c</sup> Andrew Clarke, MBBS,<sup>c</sup> Paul A. Grayburn, MD,<sup>d</sup> Robert C. Stoler, MD,<sup>d</sup> Gry Dahle, MD,<sup>e</sup> Kjell A. Rein, MD,<sup>e</sup> Marty Shaw, MBBS,<sup>a</sup> Gregory M. Scalia, MBBS,<sup>c</sup> Mayra Guerrero, MD,<sup>f</sup> Paul Pearson, MD,<sup>f</sup> Samir Kapadia, MD,<sup>g</sup> Marc Gillinov, MD,<sup>g</sup> Augusto Pichard, MD,<sup>h</sup> Paul Corso, MD,<sup>h</sup> Jeffrey Popma, MD,<sup>j</sup> Michael Chuang, MD,<sup>j</sup> Philipp Blanke, MD,<sup>j</sup> Jonathon Leipsic, MD,<sup>j</sup> Paul Sorajja, MD,<sup>b</sup> on behalf of the Tendyne Global Feasibility Trial Investigators

O/30 cardiovascular deaths at 30 days 1/3 (3.3%) noncardiovascular death (Hosp acq pneumonia) 0/30 strokes 0/30 acute MIs





#### **TMVR** Devices

- Multiple device designs resemble surgical bioprosthetic valves
- Differences in leaflet tissue
  - Porcine vs bovine pericardium
- Differences in anchoring
  - Apical tether, annular fixation, leaflet clips, other
- First-in-human trials underway in Europe, Asia, United States



## Challenges

- Mitral anatomy/function complex
- Mitral annular calcium
- Large device profiles
- Delivery systems large, mostly transapical
- LVOT obstruction / SAM
- Anchoring
- Paravalvular MR / hemolysis
- Device thrombosis
- Device-specific imaging needs

Multidisciplinary Mitral Valve Clinic



